Protocol Ledger

NCT06263231 · Phase III · RECRUITING

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

Interventional Phase III clinical trial protocol NCT06263231 sponsored by Intensity Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-28 Enrollment: 333 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06263231
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)333 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06263231
Protocol FieldVerified Registry Value
NCT IdentifierNCT06263231
Consolidated Lead SponsorIntensity Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment333 participants (ESTIMATED)
Registered Start Date2024-06-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI